Home
Directory
MapJobsInsightsNewsLearn More
Claim Your Page

A discovery platform for biotech and life sciences, built to improve visibility, discovery, and connection across the ecosystem.

Follow Us

Explore

  • Directory
  • Categories
  • Map
  • Jobs
  • Insights
  • News
  • Learn More
  • Claim Your Page
  • Help & Support

Grow with Benchscope

  • Upgrade to Premium
  • Post a Job
  • Sponsor a Focus Area
  • Data Licensing
  • Press Enquiries

© 2026 Benchscope Ltd. All rights reserved.

Benchscope Ltd is registered in England and Wales. Company number: 16664850. Registered office: 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ.

Privacy PolicyTerms of ServiceCookie Policy
Directory

Oncolytic Virus Companies in the UK

Oncolytic virus companies develop engineered or naturally occurring viruses that selectively infect and destroy cancer cells. These therapies can also stimulate anti-tumour immune responses, supporting their use alone or alongside other forms of cancer immunotherapy.

This category includes companies working on:

  • Engineered oncolytic viruses and viral vectors
  • Tumour-selective infection and cell killing
  • Cancer vaccines and immune stimulation
  • Combination therapies with checkpoint inhibitors
  • Oncolytic virotherapy development and manufacturing

Browse 7 UK oncolytic virus companies below.

View full directory
Oncolytic Virotherapy

Benchscope

Sponsored

Reach decision-makers with Benchscope

Put your company in front of buyers, partners and investors as they discover suppliers, innovators and opportunities across the UK life sciences ecosystem.

Showing 1–7 of 7
Sort by

Akamis Bio

South East England

Viral vector platform for solid tumour immunotherapy

Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour…

Biotech
View profile

PsiVac

Greater London

Oncolytic adenovirus therapeutics for solid tumour cancer treatment

PsiVac is a UK-based biotechnology company developing oncolytic virus therapeutics for the treatment of cancer. Its patented technology uses genetically modified adenoviruses…

Biotech
View profile

Bioarchitech

South East England

Oncolytic virus immunotherapies engineered to destroy solid tumours

Bioarchitech is a preclinical-stage biotechnology company developing oncolytic virus-based immunotherapies for the treatment of common solid tumours. The company engineers…

Biotech
View profile

Accession Therapeutics

South East England

Oncolytic virus platform for tumour-targeted cancer immunotherapy

Accession Therapeutics is a clinical-stage biotechnology company developing tumour-targeted immunotherapies based on its proprietary oncolytic virus platform. Designed for…

Biopharma
View profile

Replimune

South East England

Clinical-stage developer of oncolytic immunotherapies for cancer treatment

Replimune is the UK research and development site of Replimune Group, a clinical-stage biotechnology company developing oncolytic immunotherapies for cancer. Its platform uses…

Biotech
View profile

Theolytics

South East England

Oncolytic viral therapies engineered for intravenous cancer treatment

Theolytics is a clinical-stage biotechnology company developing oncolytic viral therapies for cancer. Its phenotypic screening platform enables the discovery and development of…

Biotech
View profile

VacV Biotherapeutics

Greater London

Oncolytic vaccinia virus platform targeting refractory solid tumours

VacV Biotherapeutics is a cancer immunotherapy company developing engineered oncolytic Vaccinia virus-based therapeutics for the treatment of solid tumours. Spun out of Barts…

Biotech
View profile
Related areas: Oncology·Immunology·Cell & Gene Therapy·Biotech

Benchscope

Sponsored

Sponsor your focus area

Reach buyers and partners across relevant directory pages and company profiles.

Premium Profiles

Upgrade your visibility on Benchscope

Promote your company with a premium or featured profile and stand out to biotech buyers, partners, and decision-makers exploring the directory.

Explore Premium